- Previous Close
173.40 - Open
173.28 - Bid 162.71 x 100
- Ask 164.69 x 100
- Day's Range
162.32 - 174.43 - 52 Week Range
107.50 - 219.34 - Volume
541,313 - Avg. Volume
239,546 - Market Cap (intraday)
4.706B - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
91.93 - EPS (TTM)
1.78 - Earnings Date Feb 24, 2025 - Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
207.78
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
www.krystalbio.comRecent News: KRYS
View MorePerformance Overview: KRYS
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRYS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRYS
View MoreValuation Measures
Market Cap
4.71B
Enterprise Value
4.13B
Trailing P/E
91.93
Forward P/E
29.41
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.96
Price/Book (mrq)
5.31
Enterprise Value/Revenue
17.08
Enterprise Value/EBITDA
22.78
Financial Highlights
Profitability and Income Statement
Profit Margin
21.68%
Return on Assets (ttm)
4.58%
Return on Equity (ttm)
6.38%
Revenue (ttm)
241.52M
Net Income Avi to Common (ttm)
52.37M
Diluted EPS (ttm)
1.78
Balance Sheet and Cash Flow
Total Cash (mrq)
588.32M
Total Debt/Equity (mrq)
0.84%
Levered Free Cash Flow (ttm)
42.38M